Loading...
4 results
Search Results
Now showing 1 - 4 of 4
- Exploration of biomedical dendrimer space based on in-vitro physicochemical parameters: key factor analysis (Part 1)Publication . Mignani, Serge; Rodrigues, João; Roy, René; Shi, Xiangyang; Ceña, Valentin; El Kazzouli, Saïd; Majoral, Jean-PierreDendrimers are highly branched, star-shaped macromolecules with nanometer-scale dimensions that can be readily modified with a range of functional groups, thus modifying their physicochemical and biological properties. In nanomedicine, dendrimers can be used as vectors for the targeted delivery strategy of a variety of biologically active agents or can be used as drug per se. In the future, it will be necessary to designate and develop 'safe' dendrimers, which is currently a crucial concern. Here, we analyze the key in vitro physicochemical parameters to be considered for preclinical evaluation of biomedical dendrimers.
- Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: key factor analysis (Part 2)Publication . Mignani, Serge; Rodrigues, João; Roy, René; Shi, Xiangyang; Ceña, Valentin; El Kazzouli, Saïd; Majoral, Jean-PierreIn nanomedicine, the widespread concern of nanoparticles in general, and dendrimers, in particular, is the analysis of key in-vivo physicochemical parameters to ensure the preclinical and clinical development of 'safe' bioactive nanomaterials. It is clear that for biomedical applications, biocompatible dendrimers, used as nanocarriers or active per se, should be devoid of toxicity and immunogenicity, and have adequate PK/PD behaviors (adequate exposure) in order to diffuse in different tissues. Functionalization of dendrimers has a dramatic effect on in-vivo physicochemical parameters. In this review, we highlighted key in-vivo physicochemical properties, based on data from biochemical, cellular and animal models, to provide biocompatible dendrimers. Up-to-date, only scarce studies have been described on this topic.
- Dendrimers toward translational nanotherapeutics: concise key step analysisPublication . Mignani, Serge; Shi, Xiangyang; Rodrigues, João; Roy, René; Muñoz-Fernández, Ángeles; Ceña, Valentin; Majoral, Jean PierreThe goal of nanomedicine is to address specific clinical problems optimally, to fight human diseases, and to find clinical relevance to change clinical practice. Nanomedicine is poised to revolutionize medicine via the development of more precise diagnostic and therapeutic tools. The field of nanomedicine encompasses numerous features and therapeutic disciplines. A plethora of nanomolecular structures have been engineered and developed for therapeutic applications based on their multitasking abilities and the wide functionalization of their core scaffolds and surface groups. Within nanoparticles used for nanomedicine, dendrimers as well polymers have demonstrated strong potential as nanocarriers, therapeutic agents, and imaging contrast agents. In this review, we present and discuss the different criteria and parameters to be addressed to prepare and develop druggable nanoparticles in general and dendrimers in particular. We also describe the major requirements, included in the preclinical and clinical roadmap, for NPs/dendrimers for the preclinical stage to commercialization. Ultimately, we raise the clinical translation of new nanomedicine issues.
- Bench-to-bedside translation of dendrimers: reality or utopia? A concise analysisPublication . Mignani, Serge; Rodrigues, João; Tomás, Helena; Roy, René; Shi, Xiangyang; Majoral, Jean-PierreNanomedicine, which is an application of nanotechnologies in healthcare is developed to improve the treatments and lives of patients suffering from a range of disorders and to increase the successes of drug candidates. Within the nanotechnology universe, the remarkable unique and tunable properties of dendrimers have made them promising tools for diverse biomedical applications such as drug delivery, gene therapy and diagnostic. Up-to-date, very few dendrimers has yet gained regulatory approval for systemic administration, why? In this critical review, we briefly focus on the list of desired basic dendrimer requirements for decision-making purpose by the scientists (go/no-go decision), in early development stages, to become clinical candidates, and to move towards Investigational New Drugs (IND) application submission. In addition, the successful translation between research and clinic should be performed by the implementation of a simple roadmap to jump the 'valley of death' successfully.